Core Viewpoint - Wang Zhentao, the actual controller of Kanghua Biological, plans to transfer the company's control, which may be a self-rescue move to alleviate financial pressure as both Kanghua Biological and Aokang International face development difficulties [1][2][4]. Company Overview - Kanghua Biological specializes in human vaccines, with its core product being the freeze-dried human rabies vaccine, the first of its kind in China [4][9]. - Aokang International, known as "China's first men's shoe stock," was founded by Wang Zhentao and has expanded into a diversified group covering shoes, vaccines, finance, and real estate [6][11]. Financial Performance - Kanghua Biological's net profit has declined for three consecutive years, with revenues of 14.47 billion, 15.77 billion, and 14.32 billion yuan from 2022 to 2024, and net profits of 5.98 billion, 5.09 billion, and 3.99 billion yuan respectively [9][10]. - In Q1 2025, Kanghua Biological reported a revenue of 1.38 billion yuan, down 55.7% year-on-year, and a net profit of 20.71 million yuan, down 86.15% [10]. - Aokang International's revenue has also decreased, with figures of 27.5 billion, 30.86 billion, and 25.39 billion yuan from 2022 to 2024, and net losses of 3.74 billion, 932.79 million, and 2.16 billion yuan respectively [11][12]. Shareholding and Control - Wang Zhentao directly holds 10.53% of Kanghua Biological and controls a total of 19% of the shares through Aokang Group [4][9]. - The high pledge ratio of Wang Zhentao's shares is concerning, with 89% of his shares in Kanghua Biological and 99% in Aokang International being pledged [16]. Market Reaction - Following the announcement of the potential control transfer, Kanghua Biological's stock surged by 16.2%, closing at 72.01 yuan per share, with a market capitalization of 9.574 billion yuan [4][9].

Core Viewpoint - Kanghua Biological is undergoing a change in its actual controller, which may impact its future operations and ownership structure [2] Company Overview - Kanghua Biological, founded in 2004 and listed on the ChiNext board in 2020, specializes in vaccine development, primarily focusing on rabies vaccines and meningococcal polysaccharide vaccines [4] - The company has seen a significant decline in performance, with over 90% of its revenue historically coming from a single product, the freeze-dried rabies vaccine [4][6] Financial Performance - Kanghua Biological's revenue from 2020 to 2023 showed a steady increase, reaching 1.577 billion in 2023, but the net profit has been declining since its peak of 829 million in 2021, dropping to 509 million in 2023 [4][5] - In 2024, the company reported a revenue of 1.432 billion, a year-on-year decline of 9.23%, and a net profit of 399 million, down 21.71% [5] - The core reason for the performance decline is attributed to a drastic drop in the approval quantity of its main product, with a 43.83% decrease in the number of rabies vaccine batches approved [6] Ownership and Control - Wang Zhentao, the actual controller of Kanghua Biological, holds 19.02% of the company's shares and is known for his previous success in the shoe industry [3][4] - The announcement of the control change comes after Wang's significant financial challenges, including high stock pledge rates and investigations by the China Securities Regulatory Commission for fund misappropriation [13][15] Market Context - The shoe industry, particularly for Wang's previous company, Aokang International, has faced declining demand, with production dropping from 4.618 billion pairs in 2016 to 3.524 billion pairs in 2021, and projections indicating further contraction [12] - Aokang International has also reported continuous losses since 2022, further complicating Wang's financial situation [9]

Core Points - The company announced a cash dividend distribution of RMB 0.15 per share (including tax) for its A shares [1] - The total cash dividend to be distributed amounts to RMB 60,147,000 (including tax) based on a total share capital of 400,980,000 shares [1] - The dividend distribution plan was approved at the annual general meeting on May 12, 2025 [1] Distribution Dates - The record date for the dividend is May 23, 2025, with the last trading day on May 26, 2025, and the ex-dividend date also on May 26, 2025 [1] - Cash dividends will be distributed on the ex-dividend date to shareholders registered by the end of trading on the record date [1] Implementation Method - Cash dividends for unrestricted circulating shares will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [1] - Shareholders who have not completed designated transactions will have their dividends held by the clearing company until the transactions are completed [1] Taxation Information - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of RMB 0.15 per share [2] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated upon the sale of the shares [2] - For foreign institutional investors, the company will withhold tax according to relevant regulations, resulting in a net distribution of RMB 0.135 per share after a 10% withholding tax [4]

Group 1 - The U.S. government is investigating national security risks associated with reliance on imported critical minerals and their derivatives [2] - U.S.-EU trade negotiations are stalled, with the U.S. refusing to eliminate most tariffs and seeking higher drug prices from the EU [2] - Canada has announced the removal of some countermeasures on U.S. imported cars to support its domestic automotive industry [2] Group 2 - U.S. stock markets opened high but closed lower, with the Nasdaq down 0.05%, S&P 500 down 0.17%, and Dow Jones down 0.39% [3][5] - Major tech stocks showed mixed results, with Netflix up over 4% and Nvidia down over 6% after facing export restrictions [3][8] - Chinese concept stocks mostly declined, with Zeekr down 8.84% and Xpeng down over 6% [3] Group 3 - Nvidia's stock fell over 6% due to a $5.5 billion quarterly expense related to U.S. export restrictions on H20 GPUs [8] - The U.S. Treasury Secretary expressed hope for a significant trade agreement with Beijing, emphasizing the unsustainable nature of current tariffs [11] - Brazil has overtaken the U.S. as China's largest soybean supplier, with significant purchases made recently [12] Group 4 - Xpeng Motors plans to launch its first flying car, priced under $300,000, with a production target of 10,000 units annually [14] - Tesla's CEO announced an upcoming fully autonomous driving solution based on AI technology [15] - LVMH's Q1 sales fell 3% to €20.31 billion, leading to a drop in stock price and allowing Hermès to surpass it as the most valuable luxury brand [17]

目 录 | 一、审计报告……………………………………………………… 第 1—6 页 | | --- | | 二、财务报表……………………………………………………… 第 7—14 页 | | （一）合并资产负债表…………………………………………… 第 7 页 | | （二）母公司资产负债表………………………………………… 第 8 页 | | （三）合并利润表………………………………………………… 第 9 页 | | （四）母公司利润表………………………………………………第 10 页 | | （五）合并现金流量表……………………………………………第 11 页 | | （六）母公司现金流量表…………………………………………第 12 页 | | （七）合并所有者权益变动表……………………………………第 13 页 | | （八）母公司所有者权益变动表…………………………………第 14 页 | 三、财务报表附注……………………………………………… 第 15—89 页 四、资质证书复印件…………………………………………… 第 90—93 页 审 计 报 告 天健审〔2025〕7-367 号 浙江奥康鞋业股份有限公司全体股东 ...

根据《上市公司独立董事规则》等有关规定，作为浙江奥康鞋业股份有限公 司（以下简称"公司"）的独立董事，我们认真阅读了《关于公司续聘会计师事 务所的议案》的相关资料，现就上述事项发表事前认可意见如下： 独立董事：林宗纯 BINGSHENG TENG 周俊明 一、 关于公司续聘会计师事务所的事项 2025 年 4 月 14 日 浙江奥康鞋业股份有限公司独立董事 关于第八届董事会第十五次会议 相关事项的事前认可意见 天健会计师事务所（特殊普通合伙）具备相应的执业资质和胜任能力，具备 上市公司审计服务经验，能够满足公司年度财务审计和内部控制审计工作要求， 我们同意将《关于公司续聘会计师事务所的议案》提交公司第八届董事会第十五 次会议审议。 ...

浙江奥康鞋业股份有限公司 独立董事林宗纯 2024 年度述职报告 作为浙江奥康鞋业股份有限公司（以下简称"公司"）的独立董事，在 2024 年度工作中，本人严格按照《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《浙江奥康鞋 业股份有限公司公司章程》等相关规定和要求，忠实履行独立董事职责，认真审 议董事会各项议案，充分发挥独立董事的作用，切实维护公司利益和中小股东的 合法权益，现将 2024 年度履职情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人林宗纯，男，出生于 1975 年 9 月 20 日，中国国籍，无境外永久居留权， 硕士学历，会计学教授。专注于会计/税务/审计教学与科研工作，发表论文《财 务视角下制约企业上市的因素及对策分析——以温州地区为例》，现任温州职业 技术学院会计学教授，2022 年 12 月 30 日起至今公司独立董事。 （二）是否存在影响独立性的情况说明 经自查，作为公司的独立董事，本人未在公司担任除独立董事以外的任何职 务,也未在公司主要股东处担任任何职务,与公司以及公司主要股东 ...

作为浙江奥康鞋业股份有限公司（以下简称"公司"）的独立董事，在 2024 年度工作中，本人严格按照《中华人民共和国公司法》、《中华人民共和国证券法》、 《上市公司独立董事管理办法》、《上海证券交易所股票上市规则》、《浙江奥康鞋 业股份有限公司公司章程》等相关规定和要求，忠实履行独立董事职责，认真审 议董事会各项议案，充分发挥独立董事的作用，切实维护公司利益和中小股东的 合法权益，现将 2024 年度履职情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 本人 BINGSHENG TENG（滕斌圣），男，出生于 1970 年 10 月 17 日，美国国 籍，有境外永久居留权。曾在美国乔治华盛顿大学担任助理教授和副教授，期间 获得科瑞研究学者的荣誉称号。现任长江商学院副院长、战略学教授、独角兽研 究中心主任、长飞光纤光缆股份有限公司独立董事。2022 年 8 月 11 日起至今任 公司独立董事职务。 浙江奥康鞋业股份有限公司 独立董事 BINGSHENG TENG 2024 年度述职报告 （二）是否存在影响独立性的情况说明 经自查，作为公司的独立董事，本人未在公司担任除独立董事以外的 ...

浙江奥康鞋业股份有限公司 独立董事关于第八届董事会第十五次会议 相关事项的独立意见 作为浙江奥康鞋业股份有限公司（以下简称"公司"）的独立董事，根据中 国证券监督管理委员会《上市公司独立董事规则》及《浙江奥康鞋业股份有限公 司章程》（以下简称"《公司章程》"）的有关规定，就公司 2025 年 4 月 14 日召开 的第八届董事会第十五次会议审议的相关事项，现发表独立意见如下： 二、 关于公司 2024 年度董事、高级管理人员薪酬情况的独立意见 经核查，2024 年度董事、高级管理人员薪酬符合国家有关法律法规及《公 司章程》的规定，不存在损害公司和股东利益的情形。在审议议案时，关联董事 均已回避了表决，表决程序符合有关法律法规的规定。我们同意公司 2024 年董 事及高级管理人员的薪酬发放，其中董事薪酬情况，尚需提交公司股东大会审议。 三、 关于公司 2024 年度内部控制评价报告的独立意见 经核查，我们认为公司建立了较为完善的内部控制体系，各项内部控制制度 符合我国法律法规和监管规则的要求，且能够得到有效执行，能够合理保证公司 经营管理合法合规、资产安全及财务报告真实完整。《公司 2024 年度内部控制评 价 ...

董事会 2025 年 4 月 16 日 根据中国证券监督管理委员会《上市公司独立董事管理办法》、《上海证券交 易所股票上市规则》、《上市公司自律监管指引第 1 号--规范运作》等要求，浙江 奥康鞋业股份有限公司（以下简称"公司"）董事会，就公司在任独立董事 BINGSHENG TENG、林宗纯、周俊明的独立性情况进行评估并出具如下专项意见： 经核查独立董事 BINGSHENG TENG、林宗纯、周俊明的任职经历以及签署的 相关自查文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司 主要股东公司担任任何职务，与公司以及主要股东之间不存在利害关系或其他可 能妨碍其进行独立客观判断的关系，因此，公司独立董事符合《上市公司独立董 事管理办法》、《上海证券交易所上市公司自律监管指引第 1 号--规范运作》中对 独立董事独立性的相关要求。 浙江奥康鞋业股份有限公司 浙江奥康鞋业份有限公司董事会 关于独立董事独立性情况的专项意见 ...